posted
REGN research update: Cancer Vaccine; IL-1 Trap Shows Positive Results in Study of Patients with Inflammatory Disease
233 words 16 July 2005 Obesity, Fitness & Wellness Week 289 English (c) Copyright 2005 Obesity, Fitness & Wellness Week via NewsRx.com
2005 JUL 16 - (NewsRx.com) -- Regeneron Pharmaceuticals, Inc. announced positive preliminary results from an ongoing pilot study of once-weekly dosing of the Interleukin-1 (IL-1) Trap in patients with CIAS1-associated periodic syndrome (CAPS), a family of autoinflammatory diseases.
All four patients enrolled in the study to date experienced a positive response to a subcutaneous loading dose regimen of the IL-1 Trap, including a sizable reduction in daily patient diary scores and acute phase reactant levels. In the ongoing chronic dosing phase of the study, these patients continue to demonstrate a positive response to the IL-1 Trap.
The study was conducted under a Cooperative Research and Development Agreement (CRADA) with the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), part of the National Institutes of Health.
The senior investigators in this study are Raphaela Goldbach-Mansky, M.D., Staff Clinician with NIAMS, and Daniel Kastner, M.D., Ph.D., Chief, Genetics and Genomics Branch with NIAMS. The United States Food and Drug Administration (FDA) has granted Orphan Drug Designation to the IL-1 Trap in CAPS disorders. Currently, there are no approved therapies for CAPS disorders.
This article was prepared by Obesity, Fitness & Wellness Week editors from staff and other reports. Copyright 2005, Obesity, Fitness & Wellness Week via NewsRx.com.
posted
REGN target $15 with its new research (side effect) on eye disease. FA is ranked above B+ by valueLine and $25 target by 2008. REGN's cash and profit getting better and better. I am holding several thousand shares of REGN from under $9. Will see over $10 soon.
IP: Logged |
<cashmakers>
unregistered
posted
LAZ head to its IPO $25. Target $26.5 in the next couple of weeks. TA looks attractive.
IP: Logged |
posted
REGN is the best Biotech stock this year. from both TA and RA and their disease research and cancer drugs, the stock looks charming. Still a good time to buy. REGN trade average @20 last several years. I am holding it to $15.
IP: Logged |
posted
THis is why LAZ worth at least $26.5 Take a look at this link and you will know why LAZ target is $26.5. However my target is not just based on these analyst opinion, but from FA my model. http://finance.yahoo.com/q/ao?s=LAZ
Article from WJS: U.S. deal makers still lead the M&A world
July 14th 2005 AFX Asia (c) 2005, AFX Asia. All rights reserved.
NEW YORK (XFN-ASIA) - When Chinese oil company CNOOC Ltd. Stunned the markets by making a $18.5 billion bid for Unocal Corp. last month, it didn't lean on China's burgeoning banking industry.
Nor did the company go to any Asian-based firm to advise them on the deal. Instead, like many foreign companies, it sought American-made advice from Goldman Sachs Group Inc. , J.P. Morgan Chase and legal advice from Davis Polk & Wardwell.
As CNOOC's choice suggests, Chinese mergers and acquisitions may be grabbing headlines, but U.S. investment banks continue to be grabbing the fees for advising on deals.
"They have a vast wealth of experience, detailed home country knowledge and are very adroit at hiring people from every country," said James Owers, a Harvard University associate and finance professor at Georgia State University. "When you overlay that with the traditional experience you have competitive advantage."
Indeed, though M&A is up in countries around the world, including Japan, the United Kingdom, Italy, Germany, Spain and Russia, the U.S. market remains the hottest with $593 billion in deals through the first half of the year, up 35%, according to Dealogic.
China's M&A market is actually having a slower year through the first half, down 15% to $23 billion. That puts the People's Republic 11th globally behind countries like Canada, Australia and the Netherlands.
U.S. leaders
Through the first half of 2005, four of the top five global advisers were U.S.-based firms: Morgan Stanley , Goldman Sachs, Merrill Lynch & Co. and J. P. Morgan ranked one through four. Swiss bank UBS placed fifth.
Owers cautions that U.S. banks and sellers such as Unocal may learn a lesson from the late 1980s and early 1990s. At that time, foreign buyers, including many from Japan, bought U.S. assets. The fear about foreign ownership incited nationalism and protectionism, Owers said. But, in the end, the sellers and bankers were the ones who profited.
"If someone offers you more than market price, give them the keys and let them drive it away," Owers said.
Shrinking competition
It was only a few years ago when firms such as Lazard Ltd., Cazenove, and Schroeders were considered top competitors emerging from Europe.
But Lazard booted its European management for U.S. banker Bruce Wasserstein and went public on the New York Stock Exchange. J.P. Morgan bought a 50% stake in Cazenove in 2004 and Schroeders was acquired by Citigroup for $2.2 billion in 2000.
In their place, banks such as HSBC Holdings under John Studzinski, Deutsche Bank , Dresdner Kleinwort Wasserstein and Nomura remain second-tier players with bigger ambitions.
Even in Europe
U.S. banks remain the heavyweights in Europe taking advising roles in the two biggest deals of the year. When Bayerische Hypo Vereinsbank agreed to be acquired by UniCredito Italiano in June for $18.6 billion, J.P. Morgan, Citigroup, and Deutsche Bank advised the target. Merrill Lynch and Goldman advised the buyer.
Likewise when Pernod Richard and Fortune Brands agreed to buy Allied Domecq in April for $17.7 billion, Goldman advised Allied, three U.S. banks advised the buyer with Deutsche Bank, CSFB and BNP Paribas.
That U.S. firms are leading the deals isn't new and isn't likely to change.
"They are aggressive in their strategy," Owers said. "If you're good at something and have a good strategy...you will be dominant."
This story was supplied by MarketWatch. For further information see www. marketwatch.com.
posted
Regeneron Pharmaceuticals Attend July 22th Obesity Drug Development Summit http://www.cbinet.com/show_conference.cfm?confCode=HB549&field=daytwo
In Vivo Target Discovery and Validation by High Throughput Genome Engineering A high throughput genome engineering technology platform has been developed to determined the in vivoexpression pattern of many novel obesity and diabetes-related genes at high resolution, validate and invalidate putative targets as well as dissected important metabolic pathways. This method also provides important insights into mechanisms of novel compounds currently in development for the treatment of obesity and diabetes.
Overview of technology Validation and invalidation of diabesity targets using KO models SHIP2 lipid phosphatase as target for treatment of obesity Mark W. Sleeman, Ph.D., Director of Neural and Endocrine Biology,Regeneron Pharmaceuticals Inc.
Watch REGN these days, getting hotter and hotter. Valueline raise its timeliness on June based on REGN's much-better-than-before financial statement and its new drugs research with its target $15. Three years target from Valueline is $25.
IP: Logged |
posted
FLEX strong buy. Target $20 end of 2005. Will see appreciation recently with its earning soon this month. Market Concensus 0.16, but valueline gave out their estimate 0.18 due to the Nortel contract.
Flextronics earned $0.16 a share in the fiscal fourth quarter (ended March 31st). The top line was likely about $4.0 billion in the period. Revenues probably benefited from roughly $100 million in initial contributions from its major deal with Nortel Networks, and a moderate recovery in the telecom, computer, and consumer markets.
The core electronics manufacturing-services (EMS) business should grow at a decent pace. We look for low single- digit percentage advancements in key end markets, including cellphones and information technology. Plus, revenues from the industrial, medical, and auto industries ought to climb rapidly this year. Many additional opportunities exist in those end markets, which should comprise an increasing portion of FLEX's top line. We think FLEX will gain much new outsourcing business during fiscal 2005, thanks in part to companies looking to mitigate the impact of high energy costs.
The Nortel contract will ramp up significantly this year. Revenues from that telecom equipment manufacturer should be roughly $300 million in the June quarter, and $500 million in the September period. The agreement will likely be solidly accretive to share earnings in fiscal 2005. Acquisition costs during calendar 2005 will run about $700 million. As the contract expands to include printed circuit boards (PCBs) and enclosures, annual revenues ought to be between $2 billion and $2.1 billion.
Operating margins should continue to widen this fiscal year and next. Operating cost containment and improved capacity utilization should assist margins. Plus, a greater proportion of higher-margined products and services, such as network services and PCBs, ought to drive gross margin expansion. However, Nortel's higher-cost facilities will likely hamper margins to some degree.
Flextronics shares are a good long-term holding for risk-tolerant investors. More end-to-end supply chain service offerings, such as with Nortel, should support earnings growth out to 2008-2010. In particular, the high-margined original-design-manufacturing business is poised to deliver $4 billion annually to the top line.
IP: Logged |
posted
Bought ACN @23.56 for midterm. Accenture will probably post a share-net advance in the mid-teens on a percentage basis in fiscal 2005. (Fiscal years end August 31st). The company's February quarter was solid, and early indications are that the spring should bring even more favorable results. A recovery in the consulting business continues to gain steam despite some high-profile earnings misses at several software companies, and ACN's bookings in this area remain healthy. Conversely, outsourcing bookings remain soft, but this has a lot to do with the fact that Accenture has grown increasingly selective with the contracts it accepts. All told, earnings of $1.40 in the current fiscal year are attainable.
The dip in gross margins is likely a temporary aberration. In the last few months, gross margins have fallen about 200 basis points, and Accenture's stock price has slipped in tandem. But the drop can be tied to project delays associated with a contract with the U.K.'s National Health Service. This deal incurred a $24 million loss in the February term and is expected to yield around a $130 million loss for fiscal 2005. However, the blame is being put on another vendor's slow progress with regard to this pact, and ACN should be unscathed in the long term.
The information technology market's macroeconomic environment augurs well for Accenture's future. Discretionary spending on the IT front has been trending upward for the last several quarters. This is a favorable development that offers a solid platform for the company to parlay its hefty market position into sizable revenue and earnings growth. We do caution, however, that the landscape of this arena is complex and changes quickly.
These shares are most appealing as a long-term selection. While concerns from the aforementioned margin pressures shake out in the coming year, we expect this equity to perform in line with the overall market indices. But the picture gets much brighter out to 2008-2010. Over that span, we foresee double-digit annual advances on both the top and bottom lines. Too, recent rumblings from management indicate a growing potential to initiate a dividend, although we have not factored in that prospect yet.
Target $35 at the end of this year
-------------------- Disclaim: I don’t guarantee the accuracy of the information I post. All my posts are based on my own research. I am not a registered investment advisor and therefore I am not qualified to give you any investment advices. You Make Your Decision!
IP: Logged |
posted
Versatel Finally Bought, Tele2 Pays EUR1.3B
By Arent Jan Hesselink
" Morgan Stanley & Co (MDW) Limited acts as financial advisor to Tele2, ABN Amro Holding NV (ABN) was advisor to Apax and Versatel was advised by Lazard (LAZ). "
posted
ACN target $35, strong buy. Expanding business outsourcing to China Indian, Malasyia, etc. This is an ineviable trend. ACN is an expert in this field. Fast growing company with A financial ranking and good timeliness. Just like my previous recommend KOMG.
IP: Logged |
posted
FLEX strong buy. Target $20 Flextronics International, the world's top contract electronics manufacturer. expanding its manufacturing facilities in Malaysia to counter rising costs in China. The Singapore-based, Nasdaq-listed company plans to invest 1 billion ringgit (US$263 million) over the next 10 years to build an integrated 1.2-million-square-feet industrial park, adjacent to the Port of Tanjung Pelepas, Malaysia’s fast-growing container port.
Target $20.
-------------------- Disclaim: I don’t guarantee the accuracy of the information I post. All my posts are based on my own research. I am not a registered investment advisor and therefore I am not qualified to give you any investment advices. You Make Your Decision!
IP: Logged |
Pay attention to PAYX, RECN, RHI recent jump on the global outsourcing business expansion. ACN is one of the largest outsourcing services firms in US, this stock will follow the sector trend. My target is $30 for this one.
IP: Logged |
posted
NGPS almost $34, REGN $9.8, I call REGN $8.9 two weeks ago. Now FLEX July 26 earning, the valueline estimate beat the market consensus, I bet FLEX's earning will beat the expectation. Target $20
IP: Logged |
posted
REGN broke $10, call 8.9 two weeks ago. FLEX exceeds $ 14.1. LAZ almost back to its IPO level, will see consensus target $27 in the next couple of weeks.
IP: Logged |
Credit Suisse First Boston said strong second-quarter results from Ericsson (nasdaq: ERICY - news - people ) and Nokia (nyse: NOK - news - people ) are a positive for Flextronics International (nasdaq: FLEX - news - people )
Valueline gives higher than market expectation earning for 2Q. And Target $25 to $30 in the 2008. My target is $20 in the short term.
IP: Logged |
posted
FLEX Q1 earning tomorrow, first call estimate 0.16. S&P report is 4 stars with a target $30. Morningstar gives a 4 stars with a fair value $30 and with selling suggestion @ $37. Valueline give out stronger than market consensus Q1 which is 22 cents. Pay attention tomorrow. My target is still $30 in the next several months.
IP: Logged |
FLEX Q1 earning tomorrow, first call estimate 0.16. S&P report is 4 stars with a target $16. Morningstar gives a 4 stars with a target $16 and with selling suggestion @ $15.7. Valueline give out stronger than market consensus Q1 which is 22 cents. Pay attention tomorrow. My target is still $16 in the next several months.
-------------------- Disclaim: I don’t guarantee the accuracy of the information I post. All my posts are based on my own research. I am not a registered investment advisor and therefore I am not qualified to give you any investment advices. You Make Your Decision!
IP: Logged |
JOSEPH B. WHITE AND LEE HAWKINS JR. Wall Street Journal The Globe and Mail All material copyright Bell Globemedia Publishing Inc. or its licensors. All rights reserved.
DETROIT -- Under pressure from General Motors Corp. to make significant health care benefits concessions, the United Auto Workers union said it has hired investment bank Lazard Ltd., the New York law firm Cleary Gottlieb Steen & Hamilton LLP and Leon Potok & Co. as part of a team that will conduct an analysis of GM's finances.
A UAW spokesman said the team of financial advisers, which also includes Milliman Inc., a Washington, D.C., actuarial consulting firm, and legal and financial staff members employed by the UAW, already has been gathering information on GM's condition. “We have not set a deadline,” UAW spokesman Paul Krell said. “We are going to do this thoroughly. That's not to suggest there's any foot-dragging here.”
UAW President Ron Gettelfinger said in an interview with The Wall Street Journal in June that the UAW would hire outside advisers to examine GM's finances and management claims that the company needed substantial concessions to reduce health care costs before the expiration of the current master contract in the fall of 2007.
Lazard and Cleary declined to comment. A Milliman spokesman confirmed that Milliman will be conducting an actuarial analysis relative to GM's health care costs but didn't elaborate.
Local UAW leaders have said the company wants concessions that would save $1-billion (U.S.) a year in health care outlays and cut GM's liability for future retiree health care costs by as much as $20-billion.
IP: Logged |
posted
TA channel analysis shows LAZ touch its techincal rebounce level , it should be rebounce from here 23.8. Still hold my $26.5 target for LAZ in the next couple of month.
IP: Logged |
posted
HLTH pop, add some LAZ @ 23.6 level, due to bank sector down today, LAZ down 2% with no bad news. Market overreaction. I add more shares on LAZ.
IP: Logged |
posted
DJ Scotia Ups Flextronics Tgt To $15.10 From $13.40>FLEX
(END) Dow Jones Newswires
July 27, 2005 09:16 ET (13:16 GMT)
Credit Suisse First Boston maintained an "outperform" rating and $16 price target on Flextronics. http://www.forbes.com/markets/2005/07/26/amazon-infospace-flextronics-cx_pk_0726eyeonstocks.html?partner=yahootix
RESEARCH ALERT-Wells Fargo ups Flextronics price target to $21
July 27 2005
Reuters News (c) 2005 Reuters Limited
BANGALORE, July 27 (Reuters) -
FLEXTRONICS INTERNATIONAL LTD. Current $21 Prior Price Target $16
--Wells Fargo Securities reiterated its "buy" rating on the company's shares.
Valueline raise the Timeliness to 2 last week with a Target $25-$35 in the next three years.
-------------------- Disclaim: I don’t guarantee the accuracy of the information I post. All my posts are based on my own research. I am not a registered investment advisor and therefore I am not qualified to give you any investment advices. You Make Your Decision!
IP: Logged |
-------------------- Disclaim: I don’t guarantee the accuracy of the information I post. All my posts are based on my own research. I am not a registered investment advisor and therefore I am not qualified to give you any investment advices. You Make Your Decision!
IP: Logged |
Flextronics (FLEX ) posted first quarter earnings per share from operations of 17 cents, vs. 14 cents, on slightly higher revenue. S&P reiterate its buy opinion.
-------------------- Disclaim: I don’t guarantee the accuracy of the information I post. All my posts are based on my own research. I am not a registered investment advisor and therefore I am not qualified to give you any investment advices. You Make Your Decision!
IP: Logged |
From my TA analyst, the support point is 23.8, I added more under that price. Will see back to its IPO in the next severl weeks. LAZ's next earning will be fantastic.
LAZARD EURO Business
Berlusconi, Financiers Mull An Italian Turnaround Fund
07-28-05 12:21 PM EST MILAN -(Dow Jones)- Silvio Berlusconi and some of Italy's wealthiest men, including the Italian premier's business rival Carlo De Benedetti, are considering financing a turnaround fund aimed at reviving medium-sized Italian companies.
CDB Web Tech Investments SpA (CDB.MI) said Thursday its board had commissioned its founder and Chairman Carlo De Benedetti to conduct a feasibility study on the idea.
The listed venture capital fund said it expects the proposal to be finalized in September and that it would finance the initiative with a EUR500 million capital increase.
CDB Web Tech said it would also transfer its current businesses, excluding EUR50 million in cash, to a new company to be listed on the stock exchange.
Major investors have shown interest in the turnaround fund, CDB Web said in a statement, saying that Berlusconi's Fininvest SpA (FNV.YY) holding company was among them.
Other interested parties include Diego Della Valle, whose family controls Tod's SpA (TOD.MI), Luca Cordero di Montezemolo, chairman of Fiat SpA (FIA) and Ferrari SpA as well as the head of the Charme private equity group, CDB Web Tech said. Another prospective investor is Sopaf SpA, an investment fund run by Giorgio Magnoni, whose brother Ruggero runs Lehman Brothers Holding Inc.'s (LEH) operations in Italy.
Mediobanca SpA (MB.MI), Lazard Ltd (LAZ) and Lehman Brothers, who are advising the proposed deal, will help promote the rights issue, CDB Web said.
-------------------- Disclaim: I don’t guarantee the accuracy of the information I post. All my posts are based on my own research. I am not a registered investment advisor and therefore I am not qualified to give you any investment advices. You Make Your Decision!
IP: Logged |
First Call Estimate: Q2 $0.38, P/E Ratio: 15.53 First Call Forecast: Mean $26.67 # of Price Targets 3
LAZ's Q2 will go on to be good due to global M&A booming. We can tell this from the merge & acquisition news everyday this year. Current price level still very low, $2 from the market mean target. Especially LAZ expand its business in China due to huge chinese merge market. This is a very solid company and definately a good investment. I predict LAZ will jump $1-2 high on the earning day, just like last quareter.
-------------------- Disclaim: I don’t guarantee the accuracy of the information I post. All my posts are based on my own research. I am not a registered investment advisor and therefore I am not qualified to give you any investment advices. You Make Your Decision!
IP: Logged |
posted
Add 2K more FLEX here, still hold the target $16. Average entry price $13.5.
-------------------- Disclaim: I don’t guarantee the accuracy of the information I post. All my posts are based on my own research. I am not a registered investment advisor and therefore I am not qualified to give you any investment advices. You Make Your Decision!
IP: Logged |
posted
Lazard To Step Up M&A Advisory Service In Japan
148 words 3 August 2005 Nikkei Report English ?Copyright 2005. Nihon Keizai Shimbun, Inc. All rights reserved.
TOKYO (Nikkei)--Lazard Ltd. plans to double the staff offering advisory services on mergers and acquisitions to about 55 at its Japanese unit.
The major U.S. investment bank believes that more M&A deals will be struck in Japan now that the government is setting clearer rules for them, including regulations to govern hostile takeover attempts.
Lazard will assign to the local unit Yasushi Hatakeyama, a managing director who has been advising corporate clients about hostile takeovers in the U.S.
The Japanese unit will also step up its advisory service regarding corporate restructuring as well as its asset management operations.
Lazard's push into M&A services is expected to intensify competition among U.S. investment banks, which are active in that business segment in Japan.
(The Nihon Keizai Shimbun Wednesday morning edition)
-------------------- Disclaim: I don’t guarantee the accuracy of the information I post. All my posts are based on my own research. I am not a registered investment advisor and therefore I am not qualified to give you any investment advices. You Make Your Decision!
IP: Logged |
posted
Accenture and The Dow Chemical Company Sign Multi-Year Business Services Agreement; Accenture to Expand Its Relationship as a Strategic Services Supplier
609 words 4 August 2005 03:05 pm OsterDowJones Commodity Wire English Copyright 2005, Comtex News Network. All Rights Reserved. Standard Attribution Statement: News Provided by COMTEX.
NEW YORK--, Aug 04, 2005 (ODC via Comtex) --
Aug. 4, 2005--Accenture (NYSE: ACN) and The Dow Chemical Company (NYSE: DOW), the leading global chemical company, have signed a multi-year agreement under which Accenture will continue as a strategic services supplier and will provide a broad range of business application development, implementation and support services to Dow, extending to 2011.
As part of the new agreement, Accenture will help Dow identify value-added opportunities, develop and implement initiatives and support and improve Dow's organization. Dow will leverage Accenture's knowledge of industry practices, Dow's organization and work processes to deliver results.
The new agreement expands on an already successful long-term relationship between the two companies during which Accenture helped Dow improve IT development and support productivity by more than 45 percent and supported the implementation of key strategic initiatives over the past ten years.
As a key enabling element of its business growth agenda, Dow is developing a shared services center in Shanghai, China leveraging leadership, capabilities, resources and processes developed with Accenture. Accenture has been in Greater China since 1993 and will deliver innovative services to support Dow's growth strategy in China.
"Accenture has been instrumental in improving Dow Information Systems processes and productivity and our new multi-year agreement will build on our previous success and broaden the scope of our relationship to include shared services work process, project and support service improvements," said David Kepler, Dow's Corporate Vice President of Shared Services and Chief Information Officer.
"Accenture's proven ability to effectively team and integrate culturally with an industry leader like Dow has enabled both companies to deliver measurable results for many years," said Steven Gratto, a global lead partner in Accenture's Chemicals industry group. "We are confident that under this new agreement Accenture and Dow will be able to take this long-term and successful relationship to the next level by leveraging broader global services to support Dow's business."
About The Dow Chemical Company
Dow is a leader in science and technology, providing innovative chemical, plastic and agricultural products and services to many essential consumer markets. With annual sales of $40 billion, Dow serves customers in 175 countries and a wide range of markets that are vital to human progress: food, transportation, health and medicine, personal and home care, and building and construction, among others. Committed to the principles of sustainable development, Dow and its 43,000 employees seek to balance economic, environmental and social responsibilities. References to "Dow" or the "Company" mean The Dow Chemical Company and its consolidated subsidiaries unless otherwise expressly noted.
-------------------- Disclaim: I don’t guarantee the accuracy of the information I post. All my posts are based on my own research. I am not a registered investment advisor and therefore I am not qualified to give you any investment advices. You Make Your Decision!
IP: Logged |
posted
Kyocera closes Tijuana plant, contracts Flextronics for Americas supply
190 words 4 August 2005 Business News Americas English (c) 2005 Business News Americas (BNamericas.com)
US CDMA handset manufacturer Kyocera Wireless (KWC) has closed a manufacturing plant in Tijuana, Mexico and outsourced production for the Americas market to Flextronics, Kyocera México's director Enrique Pacheco was reported as saying by local press.
KWC set up in Mexico in 2001 and supplies the country's third and fourth placed mobile operators Iusacell and Unefon, which concentrate 30% of its Latin American sales.
"Last year we carried out a study on manufacturing production costs and opted to close the [plant], and contract a third party for manufacturing equipment," Pacheco was reported as saying.
Flextronics was selected because its Mexico plant is close to the US border, he added.
This year Kyocera plans to launch five new models, international marketing director Natasha Marvin was quoted as saying.
In June, Kyocera said it expects flat sales growth in Latin America this year with a reduction in sales in Colombia compensated by greater sales in Venezuela and Brazil.
KWC resulted from Kyocera's acquisition of a cell phone unit run by CDMA technology developer Qualcomm (Nasdaq: QCOM).
-------------------- Disclaim: I don’t guarantee the accuracy of the information I post. All my posts are based on my own research. I am not a registered investment advisor and therefore I am not qualified to give you any investment advices. You Make Your Decision!
IP: Logged |
posted
LAZ Q2 this Wednesday before Open. MM been bashing it in the last two weeks in order to absorb it low. From I-watch data, it shows that 99% of the trade are done by institution. I trace the institution action these days, it seems that they start to buy their shares back. Analyst estimate is .33 per share, my financial service shows me a better number than that. Will beat the market consensus again. Watch it Wednesday. $1-2 jump is possible.
-------------------- Disclaim: I don’t guarantee the accuracy of the information I post. All my posts are based on my own research. I am not a registered investment advisor and therefore I am not qualified to give you any investment advices. You Make Your Decision!
IP: Logged |
posted
ACN has very strong cash flow and growing potential. Still a good buy at $25. Target $40-60 for 12 month.
-------------------- Disclaim: I don’t guarantee the accuracy of the information I post. All my posts are based on my own research. I am not a registered investment advisor and therefore I am not qualified to give you any investment advices. You Make Your Decision!
IP: Logged |
posted
ACN, FLEX, RHAT, VRX, MOT, LAZ strong buy at this point.
ACN hold firmly at $25, my target >$30. FLEX overreaction on the earning and insider sell 100,000 shares recently, but still hold my target $16. RHAT due to correction after jump on the earning, now it is a good time to entry little by little. VRX recently bought a license, there is a momentuem after this news, my model show me a $22-23 target. MOT upgraded by valueline and hold a 4 stars by MorningStar. LAZ earning tomorrow before the market, 0.33 is the estimate, I believe they will go on doing good thanks to the global M&A businesses.
-------------------- Disclaim: I don’t guarantee the accuracy of the information I post. All my posts are based on my own research. I am not a registered investment advisor and therefore I am not qualified to give you any investment advices. You Make Your Decision!
IP: Logged |
UBBFriend: Email this page to someone!
Printer-friendly view of this topic
